Suresh R Ramalingam (Suresh Ramalingam, Suresh S Ramalingam)

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 57

Top Venues

Cancer

Nature communications

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Cancer research

Emory University

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Emory University Oct 01 2007

United States

Professor, Director of Medical Oncology :: Department of Hematology and Medical Oncology

Publications

Suresh R Ramalingam, Jennifer Wilkinson Carlisle
Encorafenib plus binimetinib for BRAF V600E-mutant metastatic NSCLC: clinical implications of the phase 2 PHAROS study. Future oncology (London, England) (2024)
Suresh R Ramalingam, Carissa A Gilman
Direct to Cancer: A new initiative to enhance the author experience. Cancer (2024)
Ticiana A Leal, Suresh R Ramalingam
Commemorating the 20th anniversary of the discovery of epidermal growth factor receptor mutation in lung cancer: Translational research at its best. Cancer 130 (11) (2024)
Ticiana A Leal, Suresh R Ramalingam
Commemorating the 20th anniversary of the discovery of epidermal growth factor receptor mutation in lung cancer: Translational research at its best. Cancer 130 (11) (2024)
Fatemeh Ardeshir-Larijani, Suresh R Ramalingam
The MARIPOSA trials - implications for the treatment of EGFR-mutant NSCLC. Nature reviews. Clinical oncology (2024)
Ticiana A Leal, Suresh R Ramalingam
Commemorating the 20th anniversary of the discovery of epidermal growth factor receptor mutation in lung cancer: Translational research at its best. Cancer (2024)
Zhen Chen, Karin A Vallega, Dongsheng Wang, Zihan Quan, Songqing Fan, Qiming Wang, Ticiana A Leal, Suresh R Ramalingam, Shi-Yong Sun
Inhibition of hTERT/telomerase/telomere mediates therapeutic efficacy of osimertinib in EGFR mutant lung cancer. The Journal of experimental medicine 221 (11) (2024)
Junghui Koo, Chang-Soo Seong, Rebecca E Parker, Amy Herrera, Bhakti Dwivedi, Robert A Arthur, Ashok Reddy Dinasarapu, H Richard Johnston, Henry Claussen, Carol Tucker-Burden, Suresh R Ramalingam, Haian Fu, Wei Zhou, Adam I Marcus, Melissa Gilbert-Ross
Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer. Cancer research (2024)
Junghui Koo, Chang-Soo Seong, Rebecca E Parker, Amy Herrera, Bhakti Dwivedi, Robert A Arthur, Ashok Reddy Dinasarapu, H Richard Johnston, Henry Claussen, Carol Tucker-Burden, Suresh R Ramalingam, Haian Fu, Wei Zhou, Adam I Marcus, Melissa Gilbert-Ross
Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer. Cancer research (2024)
Juliann Chmielecki, Tony Mok, Yi-Long Wu, Ji-Youn Han, Myung-Ju Ahn, Suresh R Ramalingam, Thomas John, Isamu Okamoto, James Chih-Hsin Yang, Frances A Shepherd, Krishna C Bulusu, Gianluca Laus, Barbara Collins, J Carl Barrett, Ryan J Hartmaier, Vassiliki A Papadimitrakopoulou
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial. Nature communications 14 (1) (2023)
Gregory J Riely, Egbert F Smit, Myung-Ju Ahn, Enriqueta Felip Font, Suresh R Ramalingam, Anne S Tsao, Melissa Lynne Johnson, Francesco Gelsomino, Raymond Esper, Ernest Nadal, Michael D Offin, Mariano Provencio Pulla, Jeffrey Clarke, Maen Hussain, Gregory A Otterson, Ibiayi Dagogo-Jack, Jonathan Wade Goldman, Daniel Morgensztern, Ann Alcasid, Tiziana Usari, Paul S Wissel, Keith Wilner, Nuzhat Pathan, Svitlana Tonkovyd, Bruce E Johnson
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAF V600 -Mutant Metastatic Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Se Jin Im, Rebecca C Obeng, Tahseen H Nasti, Daniel McManus, Alice Oliffson Kamphorst, Sivaram Gunisetty, Nataliya Prokhnevska, Jennifer W Carlisle, Ke Yu, Gabriel L Sica, Lucas E Cardozo, André N A Gonçalves, Haydn T Kissick, Helder Takashi Imoto Nakaya, Suresh R Ramalingam, Rafi Ahmed
Characteristics and anatomic location of PD-1 + TCF1 + stem-like CD8 T cells in chronic viral infection and cancer. Proceedings of the National Academy of Sciences of the United States of America 120 (41) (2023)
Juliann Chmielecki, Jhanelle E Gray, Ying Cheng, Yuichiro Ohe, Fumio Imamura, Byoung Chul Cho, Meng-Chih Lin, Margarita Majem, Riyaz Shah, Yuri Rukazenkov, Alexander Todd, Aleksandra Markovets, J Carl Barrett, Ryan J Hartmaier, Suresh R Ramalingam
Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nature communications 14 (1) (2023)
Juliann Chmielecki, Jhanelle E Gray, Ying Cheng, Yuichiro Ohe, Fumio Imamura, Byoung Chul Cho, Meng-Chih Lin, Margarita Majem, Riyaz Shah, Yuri Rukazenkov, Alexander Todd, Aleksandra Markovets, J Carl Barrett, Ryan J Hartmaier, Suresh R Ramalingam
Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nature communications 14 (1) (2023)
Neal S McCall, James R Janopaul-Naylor, H Scott McGinnis, Aparna H Kesarwala, Sibo Tian, William A Stokes, Joseph W Shelton, Conor E Steuer, Jennifer Wilkinson Carlisle, Ticiana A Leal, Suresh R Ramalingam, Jeffrey D Bradley, Kristin A Higgins
Safety and efficacy of durvalumab after concurrent chemoradiation in Black patients with locally advanced non-small cell lung cancer. Cancer (2023)
Jhanelle E Gray, Myung-Ju Ahn, Geoffrey R Oxnard, Frances A Shepherd, Fumio Imamura, Ying Cheng, Isamu Okamoto, Byoung Chul Cho, Meng-Chih Lin, Yi-Long Wu, Margarita Majem Tarruella, Oliver Gautschi, Michael J Boyer, Krishna C Bulusu, Aleksandra A Markovets, J Carl Barrett, Rachel Hodge, Astrid McKeown, Ryan J Hartmaier, Juliann Chmielecki, Vassiliki A Papadimitrakopoulou, Suresh R Ramalingam
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Suresh R Ramalingam
Cancer Turns 75! Cancer (2023)
Juliann Chmielecki, Tony Mok, Yi-Long Wu, Ji-Youn Han, Myung-Ju Ahn, Suresh R Ramalingam, Thomas John, Isamu Okamoto, James Chih-Hsin Yang, Frances A Shepherd, Krishna C Bulusu, Gianluca Laus, Barbara Collins, J Carl Barrett, Ryan J Hartmaier, Vassiliki A Papadimitrakopoulou
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial. Nature communications 14 (1) (2023)
Grace K Dy, Ramaswamy Govindan, Vamsidhar Velcheti, Gerald S Falchook, Antoine Italiano, Juergen Wolf, Adrian G Sacher, Toshiaki Takahashi, Suresh R Ramalingam, Christophe Dooms, Dong Wan Kim, Alfredo Addeo, Jayesh Desai, Martin Schuler, Pascale Tomasini, David S Hong, Piro Lito, Qui Tran, Simon Jones, Abraham Anderson, Antreas Hindoyan, Wendy Snyder, Ferdinandos Skoulidis, Bob T Li
Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Juliann Chmielecki, Jhanelle E Gray, Ying Cheng, Yuichiro Ohe, Fumio Imamura, Byoung Chul Cho, Meng-Chih Lin, Margarita Majem, Riyaz Shah, Yuri Rukazenkov, Alexander Todd, Aleksandra Markovets, J Carl Barrett, Ryan J Hartmaier, Suresh R Ramalingam
Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nature communications 14 (1) (2023)
Juliann Chmielecki, Tony Mok, Yi-Long Wu, Ji-Youn Han, Myung-Ju Ahn, Suresh R Ramalingam, Thomas John, Isamu Okamoto, James Chih-Hsin Yang, Frances A Shepherd, Krishna C Bulusu, Gianluca Laus, Barbara Collins, J Carl Barrett, Ryan J Hartmaier, Vassiliki A Papadimitrakopoulou
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial. Nature communications 14 (1) (2023)
Juliann Chmielecki, Jhanelle E Gray, Ying Cheng, Yuichiro Ohe, Fumio Imamura, Byoung Chul Cho, Meng-Chih Lin, Margarita Majem, Riyaz Shah, Yuri Rukazenkov, Alexander Todd, Aleksandra Markovets, J Carl Barrett, Ryan J Hartmaier, Suresh R Ramalingam
Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nature communications 14 (1) (2023)
Annapaola Mariniello, Tahseen H Nasti, Daniel Y Chang, Masao Hashimoto, Sakshi Malik, Daniel McManus, Judong Lee, Donald J McGuire, Maria Andrea Cardenas, Pablo Umaña, Valeria Nicolini, Morie A Gertz, Ananya Saha, Zachary S Buchwald, Haydn T Kissick, Ehsan Ghorani, Silvia Novello, Dario Sangiolo, Giorgio Vittorio Scagliotti, Suresh R Ramalingam, Rajesh M Valanparambil
Platinum-based chemotherapy attenuates the effector response of CD8 T cells to concomitant PD-1 blockade. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Juliann Chmielecki, Tony Mok, Yi-Long Wu, Ji-Youn Han, Myung-Ju Ahn, Suresh R Ramalingam, Thomas John, Isamu Okamoto, James Chih-Hsin Yang, Frances A Shepherd, Krishna C Bulusu, Gianluca Laus, Barbara Collins, J Carl Barrett, Ryan J Hartmaier, Vassiliki A Papadimitrakopoulou
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial. Nature communications 14 (1) (2023)
Juliann Chmielecki, Jhanelle E Gray, Ying Cheng, Yuichiro Ohe, Fumio Imamura, Byoung Chul Cho, Meng-Chih Lin, Margarita Majem, Riyaz Shah, Yuri Rukazenkov, Alexander Todd, Aleksandra Markovets, J Carl Barrett, Ryan J Hartmaier, Suresh R Ramalingam
Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nature communications 14 (1) (2023)
Masao Hashimoto, Koichi Araki, Maria Andrea Cardenas, Peng Li, Rohit R Jadhav, Haydn T Kissick, William H Hudson, Donald J McGuire, Rebecca C Obeng, Andreas Wieland, Judong Lee, Daniel T McManus, James L Ross, Se Jin Im, Junghwa Lee, Jian-Xin Lin, Bin Hu, Erin E West, Christopher D Scharer, Gordon J Freeman, Arlene H Sharpe, Suresh R Ramalingam, Alex Pellerin, Volker Teichgräber, William J Greenleaf, Christiane Neumann, Jorg J Goronzy, Pablo Umaña, Warren J Leonard, Kendall A Smith, Rajesh M Valanparambil
PD-1 combination therapy with IL-2 modifies CD8 + T cell exhaustion program. Nature 610 (7930) (2022)
Suresh R Ramalingam
Cancer matters: Now more than ever! Cancer 127 (13) (2022)
Julie R Brahmer, Jong-Seok Lee, Tudor-Eliade Ciuleanu, Reyes Bernabe Caro, Makoto Nishio, Laszlo Urban, Clarisse Audigier-Valette, Lorena Lupinacci, Randeep Sangha, Adam Pluzanski, Jacobus Burgers, Mauricio Mahave, Samreen Ahmed, Adam J Schoenfeld, Luis G Paz-Ares, Martin Reck, Hossein Borghaei, Kenneth J O'Byrne, Ravi G Gupta, Judith Bushong, Li Li, Steven I Blum, Laura J Eccles, Suresh R Ramalingam
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer in CheckMate 227. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Suresh R Ramalingam, Fadlo R Khuri
The National Cancer Act of 1971: A seminal milestone in the fight against cancer. Cancer 127 (24) (2022)
Ticiana A Leal, Suzanne E Dahlberg, Suresh R Ramalingam
Lung-MAP: A Collaborative Roadmap to Improve Cancer Outcomes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (21) (2022)
Rajesh M Valanparambil, Jennifer Wilkinson Carlisle, Susanne L Linderman, Akil Akthar, Ralph Linwood Millett, Lilin Lai, Andres Chang, Ashley Alesia McCook, Jeffrey M Switchenko, Tahseen H Nasti, Manpreet Saini, Andreas Wieland, Kelly E Manning, Madison Leigh Ellis, Kathryn M Moore, Stephanie L Foster, Katharine Floyd, Meredith E Davis-Gardner, Venkata-Viswanadh Edara, Mit Patel, Conor E Steuer, Ajay K Nooka, Felicia Green, Margaret A Johns, Fiona O'Brein, Uma Shanmugasundaram, Veronika I Zarnitsyna, Hasan Ahmed, Lindsay E Nyhoff, Grace Mantus, Michael Garett, Srilatha Edupuganti, Madhusmita Behra, Morie A Gertz, Jens Wrammert, Mehul S Suthar, Madhav V Dhodapkar, Suresh R Ramalingam, Rajesh M Valanparambil
Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (33) (2022)
Jacob M Sands, Sumithra J Mandrekar, David E Kozono, Geoffrey R Oxnard, Shauna L Hillman, Dennis A Wigle, Ramaswamy Govindan, Jennifer Wilkinson Carlisle, Jhanelle E Gray, Joseph K Salama, Luis E Raez, Apar Ganti, Nathan Foster, Shakun Malik, Jeffrey Bradley, Karen Kelly, Suresh R Ramalingam, Thomas E Stinchcombe
Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO). Immunotherapy 13 (9) (2021)
Patrick M Forde, Valsamo Anagnostou, Zhuoxin Sun, Suzanne E Dahlberg, Hedy L Kindler, Noushin Niknafs, Thomas Purcell, Rafael Santana-Davila, Arkadiusz Z Dudek, Hossein Borghaei, Mara Lanis, Zineb Belcaid, Kellie N Smith, Archana Balan, James R White, Christopher Cherry, I K Ashok Sivakumar, Xiaoshan M Shao, Hok Yee Chan, Dipika Singh, Sampriti Thapa, Peter B Illei, Drew M Pardoll, Rachel Karchin, Victor E Velculescu, Julie R Brahmer, Suresh R Ramalingam
Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. Nature medicine 27 (11) (2021)
Suresh R Ramalingam, Silvia Novello, Salih Zeki Guclu, Dmitry Bentsion, Zanete Zvirbule, Maria Szilasi, Reyes Bernabe, Konstantinos Syrigos, Lauren Averett Byers, Philip Clingan, Jair Bar, Everett E Vokes, Ramaswamy Govindan, Martin Dunbar, Peter Ansell, Lei He, Xin Huang, Vasudha Sehgal, Jaimee Glasgow, Bruce A Bach, Julien Mazieres
Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (32) (2021)
Suresh R Ramalingam, Eddie Thara, Mark M Awad, Afshin Dowlati, Basir Haque, Thomas Eldridge Stinchcombe, Grace K Dy, David R Spigel, Sharon Lu, Nithya Iyer Singh, Yongqiang Tang, Iryna Teslenko, Nicholas Iannotti
JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer. Cancer (2021)
Lei Zhu, Zhen Chen, Hongjing Zang, Songqing Fan, Jiajia Gu, Guojing Zhang, Kevin D-Y Sun, Qiming Wang, Yong He, Taofeek Kunle Owonikoko, Suresh R Ramalingam, Shi-Yong Sun
Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib. Cancer research 81 (18) (2021)
Guoqing Qian, Jianping Guo, Karin A Vallega, Changjiang Hu, Zhen Chen, Yunfu Deng, Qiming Wang, Songqing Fan, Suresh R Ramalingam, Taofeek Kunle Owonikoko, Wenyi Wei, Shi-Yong Sun
Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors. Molecular cancer research : MCR 19 (10) (2021)
Gregory J Riely, Myung-Ju Ahn, Enriqueta Felip Font, Suresh R Ramalingam, Egbert F Smit, Anne S Tsao, Ann Alcasid, Tiziana Usari, Paul S Wissel, Keith D Wilner, Bruce E Johnson
Encorafenib plus binimetinib in patients with BRAF V600 -mutant non-small cell lung cancer: phase II PHAROS study design. Future oncology (London, England) 18 (7) (2021)
Conor E Steuer, Suresh R Ramalingam
Advances in Immunotherapy and Implications for Current Practice in Non-Small-Cell Lung Cancer. JCO oncology practice 17 (11) (2021)
Bassel Nazha, Subir Goyal, Zhengjia Chen, Anne Engelhart, Jennifer Wilkinson Carlisle, Tyler J Beardslee, Harpaul Gill, Levani Odikadze, Yuan Liu, Manoj K Mishra, Suresh R Ramalingam, Taofeek Kunle Owonikoko
Efficacy and safety of immune checkpoint blockade in self-identified Black patients with advanced non-small cell lung cancer. Cancer 126 (23) (2020)
Hongjing Zang, Guoqing Qian, Dan Zong, Songqing Fan, Taofeek K Owonikoko, Suresh R Ramalingam, Shi-Yong Sun
Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589). Cancer 126 (9) (2020)
Jiajia Gu, Weilong Yao, Puyu Shi, Guojing Zhang, Taofeek K Owonikoko, Suresh R Ramalingam, Shi-Yong Sun
MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor-mutant lung cancers. Cancer 126 (16) (2020)
Timothy F Burns, Hossein Borghaei, Suresh R Ramalingam, Tony S Mok, Solange Peters
Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 38 (35) (2020)
Brian Pedro, Manali Rupji, Bhakti Dwivedi, Jeanne Kowalski, Jessica M Konen, Taofeek K Owonikoko, Suresh R Ramalingam, Paula M Vertino, Adam I Marcus
Prognostic significance of an invasive leader cell-derived mutation cluster on chromosome 16q. Cancer 126 (13) (2020)
Vassiliki A Papadimitrakopoulou, Ji-Youn Han, Myung-Ju Ahn, Suresh R Ramalingam, Angelo Delmonte, Te-Chun Hsia, Janessa Laskin, Sang-We Kim, Yong He, Chun-Ming Tsai, Toyoaki Hida, Makoto Maemondo, Terufumi Kato, Suzanne Jenkins, Sabina Patel, Xiangning Huang, Gianluca Laus, Aleksandra Markovets, Kenneth S Thress, Yi-Long Wu, Tony Mok
Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer. Cancer 126 (2) (2019)
Dylan J Martini, Meredith R Kline, Yuan Liu, Julie M Shabto, Milton A Williams, Amir Ishaq Khan, Colleen Lewis, Hannah Collins, Mehmet Akce, Haydn T Kissick, Bradley C Carthon, Walid L Shaib, Olatunji B Alese, Rathi N Pillai, Conor E Steuer, Christina S Wu, David H Lawson, Ragini R Kudchadkar, Bassel F El-Rayes, Suresh R Ramalingam, Taofeek K Owonikoko, Robert Donald Harvey, Viraj A Master, Mehmet Asim Bilen
Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials. Cancer 126 (3) (2019)
Yiting Li, Hongjing Zang, Guoqing Qian, Taofeek K Owonikoko, Suresh R Ramalingam, Shi-Yong Sun
ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib. Cancer 126 (6) (2019)
Harpaul S Gill, Suresh R Ramalingam
A new standard of care for patients with surgically unresectable stage III non-small cell lung cancer. Cancer 125 (13) (2019)
Myung-Ju Ahn, Chun-Ming Tsai, Frances A Shepherd, Lyudmila Bazhenova, Lecia V Sequist, Toyoaki Hida, James C H Yang, Suresh R Ramalingam, Tetsuya Mitsudomi, Pasi A Jänne, Helen Mann, Mireille Cantarini, Glenwood D Goss
Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies. Cancer 125 (6) (2018)
Robert H Press, Chao Zhang, Richard J Cassidy, Matthew J Ferris, Jim Zhong, Conor E Steuer, Rathi N Pillai, Taofeek K Owonikoko, Shannon Kahn, Suresh R Ramalingam, Pretesh R Patel, Walter J Curran, Hui-Kuo G Shu, Gabriel L Sica, Kristin A Higgins
Targeted sequencing and intracranial outcomes of patients with lung adenocarcinoma brain metastases treated with radiotherapy. Cancer 124 (17) (2018)
Richard J Cassidy, Xinyan Zhang, Jeffrey M Switchenko, Pretesh R Patel, Joseph W Shelton, Sibo Tian, Ronica H Nanda, Conor E Steuer, Rathi N Pillai, Taofeek K Owonikoko, Suresh R Ramalingam, Felix G Fernandez, Seth D Force, Theresa W Gillespie, Walter J Curran, Kristin A Higgins
Health care disparities among octogenarians and nonagenarians with stage III lung cancer. Cancer 124 (4) (2018)
Mehmet Asim Bilen, Dylan J Martini, Yuan Liu, Colleen Lewis, Hannah H Collins, Julie M Shabto, Mehmet Akce, Haydn T Kissick, Bradley C Carthon, Walid L Shaib, Olatunji B Alese, Rathi N Pillai, Conor E Steuer, Christina S Wu, David H Lawson, Ragini R Kudchadkar, Bassel F El-Rayes, Viraj A Master, Suresh R Ramalingam, Taofeek K Owonikoko, R Donald Harvey
The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy. Cancer 125 (1) (2018)
Rathi N Pillai, Madhusmita Behera, Taofeek K Owonikoko, Alice O Kamphorst, Suchita Pakkala, Chandra P Belani, Fadlo R Khuri, Rafi Ahmed, Suresh R Ramalingam
Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature. Cancer 124 (2) (2017)
Hazem I Assi, Alice O Kamphorst, Nour M Moukalled, Suresh R Ramalingam
Immune checkpoint inhibitors in advanced non-small cell lung cancer. Cancer 124 (2) (2017)
Kushal B Naik, Yuan Liu, Michael Goodman, Theresa W Gillespie, Allan Pickens, Seth D Force, Conor E Steuer, Taofeek K Owonikoko, Suresh R Ramalingam, Kristin Higgins, Jonathan J Beitler, Dong M Shin, Field F Willingham, Bassel El-Rayes, Jerome C Landry, Felix G Fernandez, Nabil F Saba
Concurrent chemoradiotherapy with or without surgery for patients with resectable esophageal cancer: An analysis of the National Cancer Data Base. Cancer 123 (18) (2017)
Richard J Cassidy, Xinyan Zhang, Pretesh R Patel, Joseph W Shelton, Chase E Escott, Gabriel L Sica, Michael R Rossi, Charles E Hill, Conor E Steuer, Rathi N Pillai, Suresh R Ramalingam, Taofeek K Owonikoko, Madhusmita Behera, Seth D Force, Felix G Fernandez, Walter J Curran, Kristin A Higgins
Next-generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy. Cancer 123 (19) (2017)
Rathi N Pillai, Madhusmita Behera, Lynne D Berry, Mike R Rossi, Mark G Kris, Bruce E Johnson, Paul A Bunn, Suresh R Ramalingam, Fadlo R Khuri
HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium. Cancer 123 (21) (2017)

Suresh R Ramalingam.css-eqlu8i{font-size:small;padding-left:4px;} (Suresh Ramalingam, Suresh S Ramalingam)

Publication Activity (10 Years)

Top Topics

Top Venues

Suresh R Ramalingam (Suresh Ramalingam, Suresh S Ramalingam)